Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
about
Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function.The Barcelona Hospital Clínic therapeutic apheresis database.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
P2860
Q36428104-6C2CA095-D15A-4B3A-85A4-DC0445E34790Q38859426-2BB79DC5-127B-45AD-9B37-7A2CE4952FA2Q40490106-94AA9080-4BE6-4442-B12A-CE2D3F91171AQ47575272-9243528C-3A9C-43E3-AA6E-BA8E12B6C60BQ47936522-E80C165C-A403-495D-9903-96615F969CC6Q48251584-A67EE3A4-6020-451B-854D-33D476057ECAQ49077951-E597A411-02B9-4CAA-961F-4B1A8900D883Q50092819-1E6DF2A7-0B3E-45A5-AB0B-DD8F10B5B305Q53508311-0C5F67E4-E000-4EDA-A303-ED329A008342Q54582789-EADF7099-A04C-49F2-9551-EDF0487E0A60
P2860
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Plerixafor in patients with ly ...... ntervention vs remobilization.
@en
Plerixafor in patients with ly ...... ntervention vs remobilization.
@nl
type
label
Plerixafor in patients with ly ...... ntervention vs remobilization.
@en
Plerixafor in patients with ly ...... ntervention vs remobilization.
@nl
prefLabel
Plerixafor in patients with ly ...... ntervention vs remobilization.
@en
Plerixafor in patients with ly ...... ntervention vs remobilization.
@nl
P2093
P2860
P356
P1476
Plerixafor in patients with ly ...... intervention vs remobilization
@en
P2093
A Esquirol
I Sánchez-Ortega
J M Sanchez-Villegas
J R Grifols
M Encuentra
M M Pujol-Balaguer
M Pujol-Bosch
P2860
P2888
P356
10.1038/BMT.2014.196
P407
P577
2014-09-15T00:00:00Z